By Jennifer Nash

U.S. economic growth cooled more than expected in Q4 2025, according to the BEA’s latest estimate. Real GDP rose at just a 0.7% annual rate, falling well short of the 1.4% forecast and marking a steep drop-off

EXCLUSIVE: The White House is expecting to announce an expansion of drugmakers offering discounts on TrumpRx.gov, FOX Business has learned.

As early as today, Amgen and GSK will be added to the list of prescription drug manufacturers offering discounts on the government website. That makes a total of 54 prescription medications from six pharmaceutical companies that have signed on to the most-favored-nation pricing under pressure from President Donald Trump and the threat of tariffs.

Amgen will offer medication on the website that cuts 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis.

FOX NEWS POLL: VOTERS SOUND ALARM ON HEALTHCARE COSTS

President Donald Trump speaks as Administrator for the Centers for Medicare & Medicaid Services Mehmet Oz looks on during an event on drug pricing in the South Court Auditorium on the White House campus Feb. 5, 2026, in Washington, D.C. (Nathan Howard/Getty Images)

The company plans to list Aimovig and Repatha for discounts of 62%.

GSK will discount Incruse at 55% of the retail price. The drug treats COPD and will be listed at $159.

GSK also plans to list Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%.

“GSK and Amgen connecting with TrumpRx.gov to offer prescription drugs directly to consumers at most-favored-nations pricing marks another milestone for President Trump’s affordability push,” White House spokesman Kush Desai told FOX Business. 

“TrumpRx.gov is just the beginning, however, as Americans are set to (receive) even greater drug pricing discounts, lower insurance premiums and more transparency when Congress passes President Trump’s Great Healthcare Plan.”

Amgen will offer medication on the website that cuts 80% off the retail price. (George Frey/Bloomberg via Getty Images)

The Pharmaceutical Research and Manufacturers of America represents major drug companies.

CEO Stephen Ubl believes “Government-imposed most-favored-nation policies would undermine U.S. competitiveness while doing nothing to address insurance practices that deny care and raise costs for patients.

HOUSE GOP SEEKS OFF-RAMP TO SKY-HIGH HEALTH INSURANCE COSTS FOR MILLIONS OF AMERICANS

“These policies would siphon billions from American R&D, slow the pace of cures and increase reliance on China for future innovation.”

GSK will discount Incruse at 55% of the retail price. (Jeffrey Greenberg/Universal Images Group via Getty Images)

The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Operator

Greetings, and welcome to Vaxart’s Stockholder Fireside Chat Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the webcast over to David Carey, Finn Partners.

David Carey
Finn Partners, Inc.

Good afternoon, and welcome to today’s call. Joining us from Vaxart are Steve Lo, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr. James S. Cummings, Chief Medical Officer; Jeroen Grasman, Chief Financial Officer; and Ed Berg, Senior Vice President and General Counsel.

Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company’s financial results, financial guidance, its future business strategies and operations, any partnerships with third parties, timing of any anticipated regulatory approvals or that any such approval will be obtained, the company’s future cash runway, ability to regain compliance with NASDAQ listing standards or raise capital if such listing is regained, and its product development and regulatory progress, including statements about its ongoing or planned clinical trials.

Actual results could materially differ from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process and other risks described in the Risk Factors section of Vaxart’s most recently filed annual report on Form 10-K and also on other periodic reports filed with the SEC. Vaxart undertakes no obligation to update

TORONTO, March 13, 2026 /PRNewswire/ — Thomson Reuters (TSX/Nasdaq: TRI) today filed its management proxy circular and related documents in connection with the upcoming special meeting at which shareholders will be asked to approve the proposed return of capital and share consolidation transactions, among other items. The management proxy circular and related documents are available online and for pick-up, as set out below.

The transactions consists of a special cash distribution of US$605 million in the aggregate, or approximately US$1.36 per common share (estimated based on the number of common shares issued and outstanding as of the record date and assuming no shareholders opt-out of the return of capital) followed by a consolidation of outstanding common shares (or “reverse stock split”) on a basis that is proportional to the special cash distribution. The share consolidation ratio will be based on the volume weighed average trading price of the common shares on the Nasdaq Stock Market LLC (“Nasdaq”) for the five trading days immediately prior to the return of capital becoming effective.

The proposed return of capital is intended to distribute cash on a basis that is generally expected to be tax-free for Canadian tax purposes. Shareholders who are taxable in a jurisdiction outside of Canada (including taxable U.S. resident shareholders and others) (“Eligible Opt-Out Shareholders”) will be able to opt out of the return of capital. This right to opt out is being provided to those shareholders because in jurisdictions other than Canada the tax consequences of not participating in the return of capital may be preferable to those associated with participating in the return of capital. If an Eligible Opt-Out Shareholder chooses to opt out, it will not receive the cash distribution and will continue to hold the same number of shares that it currently holds.

Details of the transaction (including information regarding the opt-out right) are described in the management proxy circular and related materials, which are available on thomsonreuters.com in the “Investor Relations” section. The documents were filed with the Canadian securities regulatory authorities on SEDAR+ and are available at www.sedarplus.com. The documents will also be furnished to the U.S. Securities and Exchange Commission through EDGAR and when filed, will be available at www.sec.gov. The documents will also be available for pick-up, free of charge, at Computershare Investor Services Inc.’s offices in Toronto, Montreal, Vancouver and Calgary. Please contact Computershare Investor Services Inc. using the phone numbers set out below for the addresses of those offices.

The special meeting of shareholders will be held on Tuesday, April 28, 2026 at 9:00 a.m. EDT (changed from the original planned time of 12:00 p.m.). The meeting will be a webcast on thomsonreuters.com in the “Investor Relations” section. Holders of Thomson Reuters common shares as of 5:00 p.m. EDT on March 6, 2026 are entitled to vote at the meeting.

Registered shareholders who have questions or need assistance voting their shares may contact Computershare Investor Services Inc. at 1.800.564.6253 (toll-free in Canada and the U.S.) or at 1.514.982.7555 (outside Canada and the U.S.). Non-registered shareholders who hold their shares indirectly through an intermediary (such as an investment dealer, stock broker, bank, trust company or other nominee) should contact their intermediary if they have questions or need assistance. Shareholders who have questions or need assistance may also contact D.F. King & Co., Inc., who is acting as Information Agent for the transaction, at 1.800.967.5068 (toll-free in Canada and the U.S.) or at 1.212.561.5870 (outside Canada and the U.S., banks, brokers and collect calls) or at the following email address: tri@dfking.com.

About Thomson Reuters

Thomson Reuters (TSX/Nasdaq: TRI) informs the way forward by bringing together the trusted content and technology that people and organizations need to make the right decisions. The company serves professionals across legal, tax, audit, accounting, compliance, government, and media. Its products combine highly specialized software and insights to empower professionals with the data, intelligence, and solutions needed to make informed decisions, and to help institutions in their pursuit of justice, truth and transparency. Reuters, part of Thomson Reuters, is the world’s leading provider of trusted journalism and news. For more information, visit thomsonreuters.com.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this news release are forward-looking within the meaning of applicable Canadian and U.S. securities laws, including the Private Securities Litigation Reform Act of 1995. These statements relating to the return of capital and share consolidation transactions and the anticipated tax treatment for shareholders participating in the return of capital and those opting out. These forward-looking statements are based on certain assumptions, including shareholder approval of the transactions, and reflect our company’s current expectations. As a result, forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations, including the risk factors discussed in materials that Thomson Reuters from time to time files with, or furnishes to, the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. There is no assurance that the return of capital and share consolidation transactions will be completed or that other events described in any forward-looking statement will materialize. Except as may be required by applicable law, Thomson Reuters disclaims any obligation to update or revise any forward-looking statements.

CONTACTS

MEDIA
Zoe ZanettosDirector, Corporate Affairs
+1 647 202 8948
zoe.zanettos@thomsonreuters.com 

INVESTORS
Gary E. Bisbee, CFA
Head of Investor Relations
+1 646 540 3249
gary.bisbee@thomsonreuters.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/thomson-reuters-files-documents-for-proposed-return-of-capital-and-share-consolidation-transactions-302713835.html

SOURCE Thomson Reuters